Under construction – not a live service
Sign in
Taking people in EstoniaNo phase

Heart Function in People With Leg Artery Disease

Studies heart pumping changes in adults with narrowed leg arteries using strain imaging.

Plain-language title generated from the registry record
Registry title: Myocardial Dysfunction Evaluation in Lower Extremity Arterial Disease Patients With Deformation Analysis

Key facts

Where
Tartu, EstoniaSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 35 and 85 years old?

Source: NCT06215248, who can take part

Where in Estonia

  • Tartu University HospitalTartu, EstoniaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Tartu University Hospital
Trial code
NCT06215248
Record updated
16 December 2025
Original description
Single centre observational study to assess lower extremity arterial disease (LEAD) patients' cardiac dysfunction with strain analyses and to assess connections between cardiac dysfunction, metabolomic changes and target organ damage in LEAD.Read full original descriptionShow less

Assessment of Dysfunction in Left Cardiac Chambers With Strain-analyses in Patients With Lower Extremity Arterial Disease

Single centre observational study to assess lower extremity arterial disease (LEAD) patients' cardiac dysfunction with strain analyses and to assess connections between cardiac dysfunction, metabolomic changes and target organ damage in LEAD.

Inclusion: Fontaine I-IV class symptoms; Confirmed diagnosis of LEAD; Age 35-85; Has to have at least of the following: hypertension, diabetes, coronary artery disease or the patient smokes.

Exclusion: Known heart failure in history; Any acute or chronic autoimmune or rheumatic disease; Cardiac structural disease in history: inflammatory, infiltrative diseases, nonischemic cardiomyopathies; Acute coronary syndrome in last 3 months; Moderate to severe cardiac valvular disease; Cardiac valvular disease operative/invasive treatment in history; Cardiac implantable electronic device (CIED); Transitory ischemic attack or stroke in last 3 months; Untreated hypertension (noninvasive blood pressure measurement ≥180/110 mmHg during recruitment); Malignant tumor with radiation treatment to thorax, oncologic or biologic treatment in history; Chronic hematologic disease (except for anemia); Acute or chronic infectious disease; Chronic severe kidney dysfunction (eGFR <30 ml/min/1,73 m²); Anemia with hemoglobin <80 g/L; Age <35 or >85 years; Malignant tumor with <5 years of remission; BMI ≥40 kg/m²; Severe COPD (GOLD C or D); Moderate to severe asthma (according to GINA 2022 criteria); Severe liver dysfunction.

ClinicalTrials.gov NCT06215248